Kryda Kristina, Naito Masaya, Fujii Takeshi, Hodge Andrew, Maeder Steven
Zoetis, Veterinary Medicine Research and Development, 333 Portage St, Kalamazoo, MI, 49007, USA.
Shokukanken Inc, 561-21 Arakuchi-Machi, Maebashi, Gunma, 379-2107, Japan.
Parasit Vectors. 2025 Mar 26;18(1):117. doi: 10.1186/s13071-025-06747-6.
Simparica Trio (Zoetis), an orally administered combination product for dogs containing sarolaner, moxidectin and pyrantel pamoate, was evaluated against Haemaphysalis longicornis, a tick species originally native to Asia but now found on multiple continents, including North America.
Two groups of eight dogs each were ranked based on pretreatment tick counts and then allocated through randomization to treatment on Day 0 with a single dose of either placebo or Simparica Trio at the minimum label dose of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin and 5 mg/kg pyrantel (as pamoate salt). Dogs were infested with 50 viable adult H. longicornis on Days -2, 5, 12, 19, 26 and 33. Tick counts were conducted for all dogs 48 h after treatment and subsequent re-infestations.
Simparica Trio was 98.9% effective in treating existing H. longicornis infestation when considering live attached (feeding) ticks. Efficacy remained > 98% in preventing re-infestation for at least 35 days, and the geometric mean live attached tick counts for Simparica Trio-treated dogs were significantly lower than for placebo-treated dogs (P < 0.0001) at all timepoints assessed in the study. Dogs treated with Simparica Trio also had significantly lower (P < 0.0001) geometric mean total live (attached and free) tick counts than placebo-treated dogs at all times. No adverse events were reported for any dogs throughout the duration of the study.
A single administration of Simparica Trio at minimum label dose was efficacious in treating and controlling adult H. longicornis in dogs for more than one month.
Simparica Trio(硕腾公司生产)是一种用于犬类的口服复方制剂,含有沙罗拉纳、莫昔克丁和吡喹酮,对长角血蜱进行了评估,长角血蜱原产于亚洲,但如今在包括北美洲在内的多个大陆均有发现。
根据治疗前蜱虫计数将两组各八只犬进行排名,然后通过随机分组,在第0天用单剂量的安慰剂或最低标签剂量(1.2毫克/千克沙罗拉纳、24微克/千克莫昔克丁和5毫克/千克吡喹酮(以双羟萘酸盐形式))的Simparica Trio进行治疗。在第-2、5、12、19、26和33天,给犬只感染50只存活的成年长角血蜱。在治疗及后续再次感染后48小时对所有犬只进行蜱虫计数。
就附着存活(正在吸血)的蜱虫而言,Simparica Trio治疗现有的长角血蜱感染的有效率为98.9%。在预防再次感染方面,疗效在至少35天内保持>98%,并且在研究评估的所有时间点,接受Simparica Trio治疗的犬只的几何平均附着存活蜱虫计数均显著低于接受安慰剂治疗的犬只(P<0.0001)。在所有时间点,接受Simparica Trio治疗的犬只的几何平均总存活(附着和游离)蜱虫计数也显著低于接受安慰剂治疗的犬只(P<0.0001)。在整个研究期间,未报告任何犬只有不良事件。
以最低标签剂量单次给予Simparica Trio可有效治疗和控制犬类的成年长角血蜱感染超过一个月。